Stay updated on BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities
Sign up to get notified when there's something new on the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page.

Latest updates to the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page
- CheckyesterdayChange DetectedThe web page has been updated to include specific drug information for Tislelizumab and has revised location details, including the addition of South Korea and Taiwan locations. The revision number has also been updated to v3.0.0.SummaryDifference5%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated from version v2.16.5 to v2.16.6.SummaryDifference0.0%
Stay in the know with updates to BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities
Enter your email address, and we'll notify you when there's something new on the BGB-A317 Clinical Trial: Safety, PK, Antitumor Activities page.